Fecal Calprotectin in Combination With Standard Blood Tests in the Diagnosis of Inflammatory Bowel Disease in Children

Ho, Shaun S C; Ross, Michael; Keenan, Jacqueline I.

doi:10.3389/fped.2020.609279

Cited by 7 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While a low calprotectin decreases the chances of IBD (particularly in combination with a low CRP), it does not eliminate IBD from the diagnosis; similarly an elevated calprotectin does not necessarily indicate IBD, particularly in patients with diarrhea-predominant IBS. 55 , 58 , 61 While most studies do not support a relationship between celiac disease and pediatric FAPDs, one Italian study found a 4-fold increase in celiac (4.4% vs 1%) in youth with IBS and another study found a borderline increase. 62 , 63 Both the American Gastroenterological Association (AGA) and the pediatric Rome committee have recommended celiac screening in IBS.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

An Update on the Assessment and Management of Pediatric Abdominal Pain

Friesen¹,

Colombo²,

Deacy³

et al. 2021

PHMT

View full text Add to dashboard Cite

Chronic abdominal pain is very common in children and adolescent and results in high personal and social costs. Most youth with chronic abdominal pain fulfill criteria for a functional abdominal pain disorder (FAPD) as defined by Rome criteria. These are complex conditions with a wide array of biological, psychological, and social factors contributing to the experience of pain. The purpose of the current review is to provide an overview of the pathophysiology of FAPDs and an up-to-date summary of the literature related to FAPDs in children and adolescents, with additional focus on several areas (eg, diet and probiotics) where patients and families frequently have questions or implement self-directed care. We also provide an approach to the assessment and treatment of pediatric FAPDs focusing on the robust literature regarding psychological interventions and much sparser literature regarding medication treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

An Update on the Assessment and Management of Pediatric Abdominal Pain

Friesen¹,

Colombo²,

Deacy³

et al. 2021

PHMT

View full text Add to dashboard Cite

show abstract

“…2G). Since fecal calprotectin (S100A8/ S100A9) is a useful screening biomarker for PIBD diagnosis in clinical practice [12,13,16], we compared the diagnostic efficacy of FCN1 with that of S100A8 and S100A9 to determine the potential clinical value of FCN1. In the colon validation set, S100A8 and S100A9 showed efficient diagnostic performance in PIBD, yielding AUCs of 0.920 and 0.877 respectively.…”

Section: The Mucosal-based Diagnostic Performance Of Fcn1 For Pibd Is...mentioning

confidence: 99%

“…Fecal calprotectin is the most documented non-invasive marker for IBD [12,13]. The use of fecal calprotectin in addition to symptoms improves the diagnostic accuracy of PIBD [14], but some PIBD patients have normal fecal calprotectin levels [15,16]. Therefore, it is still necessary to identify novel useful markers for early diagnosis of PIBD.…”

Section: Introductionmentioning

confidence: 99%

Identification of FCN1 as a novel macrophage infiltration-associated biomarker for diagnosis of pediatric inflammatory bowel diseases

et al. 2023

View full text Add to dashboard Cite

Background The incidence of pediatric inflammatory bowel disease (PIBD) has been steadily increasing globally. Delayed diagnosis of PIBD increases the risk of complications and contributes to growth retardation. To improve long-term outcomes, there is a pressing need to identify novel markers for early diagnosis of PIBD. Methods The candidate biomarkers for PIBD were identified from the GSE117993 dataset by two machine learning algorithms, namely LASSO and mSVM-RFE, and externally validated in the GSE126124 dataset and our PIBD cohort. The role of ficolin-1 (FCN1) in PIBD and its association with macrophage infiltration was investigated using the CIBERSORT method and enrichment analysis of the single-cell dataset GSE121380, and further validated using immunoblotting, qRT-PCR, and immunostaining in colon biopsies from PIBD patients, a juvenile murine DSS-induced colitis model, and THP-1-derived macrophages. Results FCN1 showed great diagnostic performance for PIBD in an independent clinical cohort with the AUC of 0.986. FCN1 expression was upregulated in both colorectal biopsies and blood samples from PIBD patients. Functionally, FCN1 was associated with immune-related processes in the colonic mucosa of PIBD patients, and correlated with increased proinflammatory M1 macrophage infiltration. Furthermore, single-cell transcriptome analysis and immunostaining revealed that FCN1 was almost exclusively expressed in macrophages infiltrating the colonic mucosa of PIBD patients, and these FCN1+ macrophages were related to hyper-inflammation. Notably, proinflammatory M1 macrophages derived from THP-1 expressed high levels of FCN1 and IL-1β, and FCN1 overexpression in THP-1-derived macrophages strongly promoted LPS-induced activation of the proinflammatory cytokine IL-1β via the NLRP3-caspase-1 axis. Conclusions FCN1 is a novel and promising diagnostic biomarker for PIBD. FCN1+ macrophages enriched in the colonic mucosa of PIBD exhibit proinflammatory phenotypes, and FCN1 promotes IL-1β maturation in macrophages via the NLRP3-caspase-1 axis.

show abstract

“…In diagnostic practice, fecal calprotectin has shown utility as a marker of intestinal inflammation. Notably, fecal calprotectin distinguishes between IBD, which is marked by increased gut permeability, from functional gastrointestinal disorders (45–47) . Together, fecal calprotectin’s abundance, stability, and specificity position it as a strong biomarker of intestinal permeability.…”

Section: Introductionmentioning

confidence: 99%

Gut inflammation associated with age and Alzheimer’s disease pathology

Heston

Hanslik

Zarbock

et al. 2022

Preprint

View full text Add to dashboard Cite

Age-related disease may be mediated by low levels of chronic inflammation ("inflammaging"). Recent work suggests that gut microbes may contribute to inflammation via degradation of the intestinal barrier. While aging and age-related diseases including Alzheimer's disease (AD) are linked to altered microbiome composition and higher levels of gut microbial components in systemic circulation, the role of intestinal inflammation and permeability per se remains unclear. To test whether greater gut inflammation is associated with older age and AD pathology, we assessed fecal samples from older adults to measure calprotectin, an established marker of intestinal inflammation which is elevated in diseases of gut barrier integrity. Here we found that calprotectin levels are higher with age, and that higher calprotectin was associated with greater amyloid burden among participants with an amyloid-confirmed AD dementia diagnosis. Calprotectin was also associated with cerebrospinal fluid markers of AD pathology and axonal degeneration, as well as with lower verbal memory function among cognitively unimpaired participants. Together, these findings suggest that intestinal inflammation may play a role in pathology development, and that it may exacerbate the progression toward AD.

show abstract

Fecal Calprotectin in Combination With Standard Blood Tests in the Diagnosis of Inflammatory Bowel Disease in Children

Cited by 7 publications

References 23 publications

An Update on the Assessment and Management of Pediatric Abdominal Pain

An Update on the Assessment and Management of Pediatric Abdominal Pain

Identification of FCN1 as a novel macrophage infiltration-associated biomarker for diagnosis of pediatric inflammatory bowel diseases

Gut inflammation associated with age and Alzheimer’s disease pathology

Contact Info

Product

Resources

About